People in the News: Matt Posard

Premium

Matt Posard has joined the board of directors of Halozyme Therapeutics, a biopharmaceutical company. Posard is currently Illumina's senior vice president and general manager of translational and consumer genomics. He has worked for the San Diego-based array vendor since 2006, serving first as its vice president of global marketing and then later as vice president of global sales. Prior to joining Illumina, Posard held various marketing positions at Gen-Probe and Biosite.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.